Get the Stockscreener App
6.70
8.47%
-0.62
Pre-market:
6.57
-0.13
-1.94%
Galecto Inc stock is traded at $6.70, with a volume of 92,717.
It is down -8.47% in the last 24 hours and up +76.78% over the past month.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
See More
Previous Close:
$7.32
Open:
$7.22
24h Volume:
92,717
Relative Volume:
0.04
Market Cap:
$8.87M
Revenue:
-
Net Income/Loss:
$-38.35M
P/E Ratio:
-4.6207
EPS:
-1.45
Net Cash Flow:
$-36.91M
1W Performance:
-8.78%
1M Performance:
+76.78%
6M Performance:
+124.08%
1Y Performance:
-0.74%
1-Day Range:
$6.66
$7.64
1-Week Range:
$6.66
$7.64
52-Week Range:
$2.01
$31.70
Galecto Inc Stock (GLTO) Company Profile
Name
Galecto Inc
Sector
Industry
Phone
45-70-70-52-10
Address
75 STATE STREET, BOSTON
Compare GLTO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLTO
Galecto Inc
|
6.70 | 9.70M | 0 | -38.35M | -36.91M | -1.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Galecto Inc Stock (GLTO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Nov-23-20 | Initiated | BofA Securities | Buy |
| Nov-23-20 | Initiated | Credit Suisse | Outperform |
| Nov-23-20 | Initiated | SVB Leerink | Outperform |
Galecto Inc Stock (GLTO) Latest News
Can Galecto Inc. stock deliver consistent earnings growthJuly 2025 Gainers & Low Drawdown Momentum Trade Ideas - newser.com
Is Galecto Inc. meeting your algorithmic filter criteria2025 Institutional Moves & Weekly Watchlist for Consistent Profits - newser.com
Galecto to Highlight GB3226 Program at ASH 2025 - The Manila Times
Galecto (NASDAQ: GLTO) sets 2 ASH 2025 posters on GB3226 dual ENL‑YEATS/FLT3 inhibitor - Stock Titan
Will Galecto Inc. see short term momentumWeekly Gains Summary & Scalable Portfolio Growth Methods - newser.com
Can Galecto Inc. stock hit analyst price targets2025 Institutional Moves & Fast Moving Market Watchlists - newser.com
Using portfolio simulators with Galecto Inc. includedTrade Risk Report & AI Driven Stock Reports - newser.com
Is a relief rally coming for Galecto Inc. holdersJuly 2025 Recap & Safe Capital Investment Plans - newser.com
Can Galecto Inc. stock weather global recessionCEO Change & Consistent Growth Equity Picks - newser.com
Why Galecto Inc. stock remains undervalued2025 Investor Takeaways & Reliable Volume Spike Alerts - newser.com
Will Galecto Inc. stock maintain dividend yieldWeekly Profit Recap & Accurate Intraday Trade Tips - newser.com
Combining price and volume data for Galecto Inc.Market Sentiment Summary & Verified Technical Trade Signals - newser.com
Is Galecto Inc. stock attractive for growth ETFs2025 Volatility Report & Fast Entry High Yield Tips - newser.com
Is Galecto Inc. stock cheap at current valuation2025 Price Targets & Technical Pattern Based Buy Signals - newser.com
How to monitor Galecto Inc. with trend dashboardsJuly 2025 Sector Moves & Fast Gain Stock Tips - newser.com
Is Galecto Inc. stock attractive for income investorsJuly 2025 Update & Growth Oriented Trading Recommendations - fcp.pa.gov.br
What drives Galecto Inc stock priceRisk-Reward Ratio Analysis & Access Free Tools and Start Investing - earlytimes.in
Galecto Inc Stock (GLTO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):